Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow <sup>18</sup>F-FDG PET in Diffuse Large B-Cell Lymphoma

Tc is the most commonly used radionuclide in the field of diagnostic imaging, a noninvasive method intended to diagnose a disease, assess the disease state and monitor the effects of treatments. Annually, the use of Tc, covers about 85% of nuclear medicine applications. This isotope releases gamma rays at about the same wavelength as conventional X-ray diagnostic equipment, and owing to its short half-life (t = 6 h) is ideal for diagnostic nuclear imaging. A patient can be injected with a small amount of Tc and within 24 h almost 94% of the injected radionuclide would have decayed and left the body, limiting the patient's radiation exposure.Tc is usually supplied to hospitals through a Mo/Tc radionuclide generator system where it is produced from the β decay of the parent nuclide Mo (t = 66 h), which is produced in nuclear reactors via neutron fission. Recently, the interruption of the global supply chain of reactor-produced Mo, has forced the scientific community to investigate alternative production routes forTc. One solution was to consider cyclotron-based methods as potential replacement of reactor-based technology and the nuclear reaction Mo(p,2n)Tc emerged as the most worthwhile approach. This review reports some achievements about Tc produced by medical cyclotrons. In particular, the available technologies for target design, the most efficient extraction and separation procedure developed for the purification ofTc from the irradiated targets, the preparation of high purity Tc radiopharmaceuticals and the first clinical studies carried out with cyclotron producedTc are described.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma

Cited by 2 publications

References 6 publications

PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma

PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma

Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons

Contact Info

Product

Resources

About

Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow 18F-FDG PET in Diffuse Large B-Cell Lymphoma

Cited by 2 publications

References 6 publications

PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma

PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma

Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons

Contact Info

Product

Resources

About

Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow ¹⁸F-FDG PET in Diffuse Large B-Cell Lymphoma